Andrew M. Blakely, M.D.

Andrew M. Blakely, M.D.
Assistant Research Physician

Team Member of:

Dr. Blakely is a surgical oncologist specializing in peritoneal surface and retroperitoneal malignancies. A primary focus of his research is to develop novel treatment approaches and modalities to improve pre-operative treatment of peritoneal carcinomatosis.

Areas of Expertise

1) peritoneal surface malignancy, 2) gastroenteropancreatic neuroendocrine tumor,
3) soft tissue sarcoma, 4) adrenocortical carcinoma

Contact Info

Andrew M. Blakely, M.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 4-3760
Bethesda, MD 20892
Ph: 240-858-3610
andrew.blakely@nih.gov

Peritoneal malignancies may arise from various organs, including but not limited to the colon, appendix, stomach, ovary, or adrenal gland. However, peritoneal tumor deposits tend to be relatively resistant to traditional intravenous systemic chemotherapy regimens that are otherwise effective for disease involving other sites, such as the liver or lungs. Administration of intraperitoneal chemotherapy allows much higher chemotherapeutic drug levels to be achieved in the peritoneal cavity, with far less systemic absorption and toxicity than if given intravenously at the same dose. However, intraperitoneal chemotherapy is only effective after cytoreductive surgery, where all disease >2.5 mm has been completely removed or ablated. Unfortunately, many patients with peritoneal carcinomatosis have high burdens of disease, which may preclude optimal cytoreduction or lead to such debilitation that extensive surgical resection would not be tolerated by the patient.

Dr. Blakely’s research primarily focuses on developing treatment strategies that bring the potential benefits of pre-operative therapy to patients with peritoneal surface malignancies. Neoadjuvant intraperitoneal chemotherapy administration may reduce peritoneal surface disease burden, which in turn facilitates or even obviates subsequent cytoreductive surgery. In addition, for patients experiencing symptomatic malignant ascites, intraperitoneal chemotherapy alone can effectively palliate unresectable patients.

NIH Scientific Focus Areas:
Biomedical Engineering and Biophysics, Cancer Biology, Clinical Research

Selected Key Publications

  1. Blakely AM, Manning KL, Tripathi A, Morgan JR.
    Tissue Engineering Part C Methods. 21(7): 737-746, 2015. [ Journal Article ]
  2. Eng OS, Raoof M, Blakely AM, Yu X, Lee SJ, Han ES, Wakabayashi, MT, Yuh B, Lee B, Dellinger TH.
    Journal of Surgical Oncology. 118(1): 121-126, 2018. [ Journal Article ]
  3. Blakely AM, Matoso A, Patil PA, Taliano R, Machan JT, Miner TJ, Lombardo KA, Resnick MB, Wang LJ.
    Histopathology. 72(3): 405-413, 2018. [ Journal Article ]
  4. Vidri RJ, Blakely AM, Kulkarni SS, Vaghjiani RG, Heffernan DS, Harrington DT, Cioffi WG, Miner TJ.
    Annals of Palliative Medicine. 4(4): 200-206, 2015. [ Journal Article ]
  5. Blakely AM, Heffernan DS, McPhillips J, Cioffi WG, Miner TJ.
    Journal of Surgical Oncology. 110(6): 615-655, 2015. [ Journal Article ]

Dr. Blakely completed a Bachelor of Science in Biomedical Engineering followed by medical school at Drexel University. He went on to general surgery residency at Brown University. During residency, he spent two years of dedicated research time at the Center for Biomedical Engineering developing a device for tissue engineering applications. That work then led to a National Science Foundation grant and a patent. Dr. Blakely then completed his fellowship in Complex General Surgical Oncology at City of Hope National Medical Center.